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Abstract Sepsis is a major cause of mortality during the
neutropenic phase after intensive cytotoxic therapies for ma-
lignancies. Improved management of sepsis during neutrope-
nia may reduce the mortality of cancer therapies. Clinical
guidelines on sepsis treatment have been published by others.
However, optimal management may differ between neutrope-
nic and non-neutropenic patients. Our aim is to give evidence-
based recommendations for haematologist, oncologists and
intensive care physicians on how to manage adult patients
with neutropenia and sepsis.
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Clinical significance and methods
Sepsis is a leading cause of mortality in patients with
haematologic malignancies or solid tumours undergoing in-
tensive cytotoxic chemotherapy [29, 168]. Therefore, optimi-
zation of diagnosis and management of sepsis could improve
outcome of intensive cytotoxic therapies. A number of prior
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guidelines on the management of sepsis have been published
[15, 41, 43, 60, 96, 106, 132, 137]; however, none of these
guidelines specifically address diagnosis and management of
sepsis in neutropenic patients.
These updated guidelines were written to provide guidance
on diagnosis and management of sepsis in the neutropenic
host. First, a panel of 13 experts in the field of infectious
diseases in haematology and oncology agreed to participate
in preparing the guidelines. Second, the guidelines were the-
matically divided into six subtopics. Then, subcommittees of
two to four authors were created, being responsible for liter-
ature search in one of the subtopics. We systematically
searched Medline for English language publications up to
June 2013 using the key terms: sepsis and one of the follow-
ing: neutropenia, bacteraemia, bloodstream infection
(bacteraemia), definition, epidemiology, incidence, risk fac-
tors, prognosis, treatment, antibiotic, antifungal, cardiovascu-
lar, pulmonary failure, ventilation, renal dysfunction, renal
failure, dialysis, haemofiltration, nutrition, hyperglycaemia,
steroid, coagulation, growth factor, immunoglobulin and
transfusion. Meeting abstracts were not included; however,
references generated from published guidelines and reviews
were also investigated. The consensus process was performed
as an email- and meeting-based discussion group. In a second
step, the manuscript draft was peer reviewed by the review
committee of the Infectious Diseases Working Party of the
German Society of Hematology and Medical Oncology
(AGIHO) on October 1st, 2013. In a third step, the guide-
lines were approved by the assembly of the members on
October 20th, 2013. Criteria used to quote levels and
grades of evidence are as outlined in Table 1 [88]. The
first draft of the manuscript was written by the subcom-
mittees. The final version of the manuscript was prepared
by the corresponding author and has been approved by all
authors.
Definitions
A formal definition of sepsis has long been tried by several
researchers andmust lack specificity given the broad spectrum
of reactions to pathogens.
We suggest using the diagnostic consensus criteria for
sepsis adapted to neutropenic patients (Table 2) [97,
98]. In neutropenic patients, the white blood cell count
cannot be used as a criterion to define sepsis. The
definitions of severe sepsis and septic shock remain
unchanged and refer to sepsis-induced organ dysfunction
(Table 3).





A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation
D Moderate evidence to support a recommendation against
use
E Good evidence to support a recommendation against use
Quality of evidence
I Evidence from ≥1 properly randomized, controlled trial
II Evidence from ≥1 well-designed clinical trial, without
randomization; from cohort or case-controlled analytic
studies (preferably from >1 centre); from multiple time-
series; or from dramatic results from uncontrolled
experiments
III Evidence from opinions of respected authorities, based on
clinical experience, descriptive studies or reports of
expert committees
Table 2 Diagnostic criteria for sepsis during neutropenia [97, 98]. In
neutropenic patients, cytopenia cannot be used as a criterion to define
sepsis
General parameters
Fever (core temperature >38.3 °C)
Hypothermia (core temperature <36.0 °C)
Heart rate (>90 bpm or >2 SD above the normal value for age)
Tachypnoea (>30 bpm)
Altered mental status
Significant edema or positive fluid balance (>20 mL/kg over 24 h)
Hyperglycaemia (plasma glucose >110 mg/dL or >7.7 mmol/L) in the
absence of diabetes
Inflammatory parameters
Plasma C reactive protein or plasma procalcitonin (>2 SD above the
normal value)
Haemodynamic parameters
Arterial hypotension (systolic blood pressure <90 mmHg, mean
arterial pressure <70 mmHg, or a systolic blood pressure decrease
>40 mmHg in or <2 SD below normal for age)
Mixed venous oxygen saturation (>70 %)
Cardiac index (>3.5 L/min/m2)
Organ dysfunction parameters
Arterial hypoxaemia (PaO2/FIO2 <300)
Acute oliguria (urine output <0.5 mL/kg/h for ≥2 h)
Creatinine increase (≥0.5 mg/dL)
Coagulation abnormalities (international normalized ratio >1.5 or
activated partial thromboplastin time >60 s)
Ileus (absent bowel sounds)
Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 mmol/L)
Tissue perfusion parameters
Hyperlactataemia (>3 mmol/L)
Decreased capillary refill or mottling
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Incidence
Systematic data evaluating the overall incidence of neutrope-
nic sepsis in cancer patients are lacking. The incidence of
febrile neutropenia and bacteraemia has been studied more
in detail, albeit the majority of studies did not use uniform
definitions, include at least partly non-neutropenic patients
and focus on distinct patient subgroups. Patients with solid
tumours develop febrile neutropenia in around 10–40 %, but
this complication might occur in more than 80 % of patients
with haematological malignancies [1, 54]. In patients with
indwelling central venous catheters (CVC), febrile neutrope-
nia is frequently caused by catheter-related or catheter-
associated bacteraemia with an incidence of around 10–20/
1,000 neutropenic days [16, 34]. Likewise, translocation of
gut organisms, such as vancomycin-resistant enterococci
(VRE), may cause bacteraemia and, ultimately, sepsis in neu-
tropenic cancer patients in up to 40 % of colonized patients
[30, 101, 154].
It can be assumed that >50 % of patients with febrile
neutropenia or bacteraemia develop sepsis using the consen-
sus definition. Severe sepsis and septic shock, which have
been investigated in a few prospective and retrospective anal-
yses, might occur in up to 20–30 and 5–10 % of patients with
febrile neutropenia, respectively [6, 78, 81, 95, 109, 112].
The increasing numbers of elderly patients undergoing
intensive treatment modalities and patients infected with
treatment-resistant organisms led to the assumption that the
frequency of neutropenic sepsis will increase [11].
Risk factors and prognosis
Prospective data of risk factors and prognosis for sepsis in
adult neutropenic patients are rare [6, 63, 78].
Risk factors for bacteraemia
There are few data on risk factors for bacteraemia during
neutropenia. Apostolopoulou et al. observed a significant
higher rate of bacteraemia, potentially resulting in sepsis, in
patients with neutropenia <0.5 g/L. Additionally, acute mye-
loid leukaemia, a prolonged hospital stay, a Hickman catheter,
or pre-treatment with antibiotics, chemotherapy or surgery
were significantly associated with BSI in haematological and
oncological patients [16].
Risk factors for development of severe sepsis
The presence of hypophosphataemia (<0.8 mmol/L) and
hypoproteinaemia (<62 g/L) have been identified as risk
factors for severe sepsis in febrile neutropenia [78]. The
development of septic shock in febrile neutropenia is inde-
pendently predicted by the presence of pulmonary infection,
tachypnoea, increased serum levels of procalcitonin
(≥1.5 ng/mL), high lactate levels [6, 109], decreased serum
levels of bicarbonate (<17 mmol/L), antithrombin (<70 %)
or factor VIIa (<0.8 ng/mL) [63, 78, 109, 135]. A low
Multinational Association for Supportive Care in Cancer
(MASCC) risk index score of <21 is associated with an in-
creased risk for septic shock in febrile neutropenic patients [6].
Prognosis
Prolonged neutropenia <0.5 g/L or the delayed initiation of
antibiotics is associated with poor clinical outcome in neutro-
penic patients with sepsis [5, 103]. Severe sepsis and septic
shock negatively influence outcome [64, 95, 162]. A recent
prospective study demonstrated mortality rates of 35 % in
severe sepsis, 47 % in septic shock and 85 % in multi-organ
failure in patients with haematological malignancies [19].
Factors that were significantly associated with hospital sur-
vival included remission of malignant tumour and time to
intensive care unit (ICU) admission <24 h. Negative predic-
tive factors for hospital survival were as follows: allogeneic
haemopoietic stem cell transplantation (HSCT), poor perfor-
mance status, invasive pulmonary aspergillosis, malignant
organ infiltration and acute respiratory failure. In another
study, Legrand et al. identified prognostic factors for neutro-
penic patients with severe sepsis or septic shock: The appear-
ance of acute non-infectious complications, of neurological,
respiratory or hepatic dysfunction, the need for vasopressor
therapy, or older age increased the mortality. On the other
hand, the early removal of a CVC and combined antibiotic
therapy were associated with higher survival [95].
Microbiology
Blood cultures as part of the usual microbiological work-up
as per local protocol (including urine cultures, stool cul-
tures etc.) remain the gold standard for the diagnosis of
bacteraemia and fungaemia. Blood cultures should be stan-
dardized in terms of volume, culture sets, frequency, pro-
cessing, interpretation and reporting.
Table 3 Definitions of severe sepsis and septic shock
Severe
sepsis
Sepsis with new signs of organ dysfunction or a decrease in
organ perfusion (lactate acidosis, oliguria (<30 mL/h or
<0.5 mL/kg/h), hypotension (<90 mmHg or decrease of
>40 mmHg), mental alteration)
Septic
shock
Severe sepsis and hypotension persistent despite adequate
fluid substitution and exclusion for other reasons for
hypotension
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However, although most episodes of febrile neutropenia
are assumed to be caused by an infection, blood cultures are
positive in less than 30% of febrile neutropenic episodes [48].
Typical organisms causing sepsis during neutropenia are sum-
marized in Table 4.
The epidemiology of gram-positive versus gram-negative
bacteraemia varies in different countries [115]. In contrast to
other countries, Germany has a predominance (>50 %) of
gram-positive bacteria as the cause for febrile neutropenia
[45]. Knowledge about the local epidemiology is essential
for a rational choice of empirical antibiotic therapy as already
pointed out by others. This is particularly true for colonization
with resistant bacteria, since these have been associated with
an increased risk of bacteraemia with these pathogens [101].
PCR-based methods to detect bacterial and fungal DNA
have yet to be validated in larger cohorts [8, 93, 105, 120,
164]. In contrast, PCR-based methods play a definitive role in
the diagnosis of viral infections, which may cause sepsis in
severely immunocompromised patients [71, 102, 129].
Treatment
Antimicrobial treatment
Empirical antimicrobial treatment using broad-spectrum anti-
biotics must be started immediately in neutropenic patients
with sepsis (AII). A large retrospective study including more
than 2,000 patients showed that during severe sepsis, effective
antimicrobial administration within the first hour of docu-
mented hypotension is associated with increased survival
[95]. In this study, each hour of delay in antimicrobial admin-
istration over the ensuing 6 h was associated with an average
decrease in survival of 7.6 % [95].
In neutropenic patients with sepsis, results from random-
ized controlled trials are lacking, and recommendations are
based on study results from non-neutropenic patients as well
as on expert opinions. We recommend initial treatment with
meropenem or with imipenem/cilastatin or with piperacillin/
tazobactam (AIII).
Meta-analyses show that a combination treatment with
aminoglycosides increased renal toxicity without improving
efficacy in neutropenic patients with bacteraemia [125–127].
However, in a retrospective study, the use of β-lactam
antibiotic/aminoglycoside combinations were associated with
superior outcome, as compared with single-agent antimicro-
bial treatment, in neutropenic patients with severe sepsis and
septic shock [95]. Another retrospective study showed re-
duced hospital mortality in non-neutropenic patients with
severe bacterial sepsis after combination therapy comprising
at least two antibiotics of different mechanisms versus antibi-
otic monotherapy [92]. Taken together, a combination treat-
ment with an aminoglycoside may be considered in neutrope-
nic patients with septic shock and severe sepsis (BIII).
Knowledge of local microbiology data is crucial for the
choice of antimicrobial agents. Importantly, local resistance
patterns as well as colonization with resistant bacteria have to
be considered [101]. If infection due to bacteria with frequent
resistance to carbapenems or piperacillin/tazobactam is
suspected, a specific antibiotic should be added (BIII). If a
specific organ infection is suspected, antibiotic therapy should
be adapted accordingly. Recommendations on antifungal ther-
apy during neutropenia were recently published by our group
and by others [55, 104, 118, 157].
Treatment of cardiovascular insufficiency
Aggressive and early goal-directed treatment aiming at resto-
ration of cardiovascular function is crucial [42, 140]. To
restore adequate cardiac filling pressures and to maintain
adequate organ perfusion (goal, mean arterial pressure
65 mmHg, central venous pressure 8–12 mmHg, pulmonary
wedge pressure 12–15 mmHg, urinary output 0.5 mL/kg/h
and central venous or mixed venous oxygen saturation 70 %),
crystalloid fluids are recommended as the initial fluid of
choice in severe sepsis and septic shock. Compared to crys-
talloids, randomized controlled trials did not show beneficial
effects of colloids, especially hydroxyethyl starches for fluid
resuscitation in sepsis [32, 62, 128]. However, the risk of acute
kidney injury requiring renal replacement therapy is substan-
tially increased by the use of hydroxyethyl starch (EI) [128].
While a large randomized study indicated that albumin
administration was safe and equally effective as 0.9 % saline
[50], a meta-analysis of data from 17 randomized trials found
that the use of albumin-containing solutions for fluid resusci-
tation of patients with sepsis was associated with lower mor-
tality compared with crystalloids [40]. However, in a
Table 4 Typical pathogens during bacterial sepsis in neutropenic patients
Origin Frequent pathogens
Unknown Coagulase-negative Staphylococci, Escherichia coli,
Enterococcus species
Lung Pseudomonas aeruginosa, Streptococcus pneumoniae
(pneumococci), Viridans (alpha-haemolytic) streptococci,
Acinetobacter species
Abdomen Escherichia coli, P. aeruginosa, Clostridium spp.,
Enterococcus spp., Klebsiella species
Urogenital Escherichia coli, Klebsiella species, Pseudomonas
aeruginosa
Soft tissue Staphylococcus aureus, alpha-haemolytic streptococci
CVC Coagulase-negative Staphylococci, Coryneform bacteria,
Propionibacterium species, Candida albicans, Candida
tropicalis, Candida parapsilosis, Stenotrophomonas
maltophilia
CVC central venous catheter
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multicenter randomized trial (n=794) in patients with septic
shock, the use of albumin therapy did not significantly reduce
28-day mortality compared to saline solution [50]. Thus,
albumin-containing solutions may be used for fluid resuscita-
tion of patients with sepsis and septic shock (CII).
If a sufficient mean arterial pressure (>65 mmHg) cannot
be achieved by volume substitution in a reasonable time
frame, treatment with vasopressors is indicated. The drug of
choice to elevate the vasotonus is norepinephrine in a dose of
0.1–1.3 μg/kg/min (BII) [48].
In retrospective and small prospective studies, vasopressin
(0.01–0.04 U/min) increased urinary output and creatinine
clearance compared to norepinephrine [51–53]. However, in
the large VASST trial, no reduction in 28-day mortality was
found in the vasopressin group, and there is currently poor
evidence to support the use of vasopressin in septic shock (CI)
[54]. In case of sepsis-related myocardial depression leading
to low cardiac output despite adequate volume substitution,
vasopressor treatment with dobutamine should be instituted
(AII) [140]. Of note, results from an observational study
suggest that dopamine administration may be associated with
increased mortality rates in septic patients [142].
Bicarbonate therapy is not recommended for the purpose of
improving haemodynamics or reducing vasopressor require-
ments in the presence of lactic acidosis and pH >7.15 (DII)
[38, 108].
Treatment of pulmonary failure
Pneumonia leading to acute respiratory failure is a major cause
of sepsis in neutropenic cancer patients [19, 20]. On the other
hand, severe sepsis may lead to acute lung injury/acute respi-
ratory distress syndrome (ARDS) [145].
In cooperative and awake patients with mild to moderate
pulmonary failure, non-invasive positive pressure ventilation
should be preferred (AII) [19, 37, 69, 70, 145]. Both non-
invasive treatment options led to a significant reduction of
intubation compared to the control group in neutropenic can-
cer patients [19, 73]. An early start of non-invasive ventila-
tion, prior to development of severe hypoxaemia, is
favourable (BII) [21]. Failure of non-invasive ventilation oc-
curs in half of the critically ill haematologic patients and is
associated with an increased mortality [21]. Predictors of non-
invasive ventilation failure are as follows: high respiratory
rate, short time between admission and non-invasive ventila-
tion [21], vasopressor use, renal replacement therapy and the
development of ARDS [3].
In moderate to severe respiratory insufficiency, endotrache-
al intubation and mechanical ventilation are necessary.
Survival is positively correlated to the experience of the ICU
with haematologic and oncologic patients [171]. In a retro-
spective multicenter study of allogeneic HSCT recipients ad-
mitted to the ICU, mechanical ventilation was associated with
low survival rates [107]. These data were confirmed in a
prospective study [19].
Percutaneous extracorporeal membrane oxygenation
showed to be a rescue therapy to bridge hypoxemia due to
ARDS in patients with oncological or malignant haematolog-
ical diseases [59, 99, 111]. Further studies are needed in this
field, before a recommendation can be given.
Management of renal dysfunction
Acute kidney injury (AKI) develops in approximately 20% of
patients with severe sepsis and 50 % with septic shock. The
combination of acute renal failure and sepsis is associatedwith
a 70 % mortality [144]. Specific data for neutropenic patients
are lacking, and recommended management of renal dysfunc-
tion is not different from non-neutropenic patients.
In short, no clear guidelines on the timing of the initiation
of renal replacement therapy (RRT) can be given. Regarding
the mode of replacement therapy, intermittent haemodialysis
and continuous renal replacement therapies (CRRT) are
equivalent in patients with sepsis and AKI (BI) [57, 58, 84,
100, 134, 155]. In haemodynamically unstable patients, con-
trol of fluid balance may be facilitated by the use of CRRT
(BII) [42, 79].
Increasing the frequency of RRT is thought to reduce the
rate of uremic complications and improve outcome in patients
with AKI. However, randomized controlled studies showed
conflicting results [42, 79, 138]. A recent meta-analysis indi-
cates that high-dose RRT in critically ill patients with AKI
does not improve patient survival or recovery of renal function
as compared with less-intensive regimes [75, 122, 160]. Thus,
no firm recommendations can be given for the increased
frequency of RRT (CI).
In patients undergoing renal replacement therapy, the dos-
age of antimicrobial substances should be carefully checked
and adjusted [86]. The use of low-dose dopamine for protec-
tion of renal function is not recommended (EI) [26, 85].
Nutrition and control of metabolic functions
Caloric intake
Most recommendations reported are extrapolated from analy-
ses in critically ill and well-nourished patients without neu-
tropenia. Enteral nutrition is preferred over parenteral nutrition
unless contraindicated or impossible, as it is associated with a
lower rate of infections (BII) [67]. Enteral caloric intake
should be calculated according to the phase of sepsis: during
the initial phase of sepsis, the supply of >20–25 kcal/kg ideal
bodyweight (IBW) has been associated with inferior outcome
in one observational study (DIII) [91]. During recovery, 25–
30 kcal/kg IBW should be provided (BIII) [89, 149].
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Supplements
As reproducible mortality benefits for supplementation of
arginine [31, 56], omega-3 fatty acids [24, 130, 131] and
combined formulations [27, 56, 68] in patients with severe
sepsis and septic shock are lacking, we do not recommend
general use of either of these supplements (DII). Substitution
of glutamine did not positively affect the primary survival
endpoint in two randomized trials including together over
1,000 patients with sepsis [9, 66] and significantly increased
in-hospital and 6-month mortality in the REDOXS study [66].
Therefore, glutamine substitution cannot be recommended
(EI).
Two recent large randomized two-factorial trials compared
the influence of lower doses of selenium substitution to pla-
cebo in critically ill patients [9, 66]. In these trials including
282 and 826 septic patients, respectively, selenium substitu-
tion had no effect onmortality [9, 66]. In a smaller trial, higher
dose selenium substitution (1,000 μg daily) was associated
with mortality reduction only in the per protocol analysis [10].
In a meta-analysis including nine trials with septic patients,
selenium substitution was associated with lower mortality,
especially in patients receiving selenium in higher doses
(≥1,000 mg daily) and for ≥6 days [74]. Thus, further clinical
trials regarding the adequate dosing and treatment duration are
needed before treatment with selenium can be recommended
(DI).
Hyperglycaemia
Hyperglycaemia in patients requiring intensive care is associ-
ated with an inferior outcome [23, 47]. Results of clinical trials
in patients with severe sepsis and septic shock [13, 32] as well
as clinical trials [51, 133, 158] including patients with under-
lying malignant disease [158] and a meta-analysis [61] in
mixed populations of critically ill patients failed to show a
benefit of intensified insulin therapy. These results are in
contrast to the results of the initial trial by van den Berghe
et al. [159] which had suggested a benefit of a tight blood
glucose control (blood glucose level of 4.4–6.6 mmol/L (80–
120 mg/dL)). Thus, we do not recommend intensive insulin
therapy aiming at a blood glucose level of 4.4–6.6 mmol/L
(80–120 mg/dL; EI). Based on these data and international
guidelines [44, 76, 137], we recommend to maintain blood
glucose levels at least ≤9.9 mmol/L (≤180 mg/dL; BIII). A
high variability of blood glucose levels in septic patients
should be avoided, as this is associated with increased mor-
tality (BIII) [7, 22, 46].
Treatment with corticosteroids
Replacement of an impaired adrenal reserve and anti-
inflammatory properties is a rationale for studying
corticosteroids as an adjunctive to sepsis therapy. The use of
corticosteroids in sepsis has not been studied in a prospective
fashion for neutropenic patients. In the CORTICUS trial, 84
cancer patients were included; however, no subgroup analysis
of these patients has been published [35].
High-dose corticosteroid treatment (>300 mg hydrocortisone
per day)
Randomized controlled trials and meta-analyses reported on
increased overall mortality and increased mortality from sec-
ondary infections in non-neutropenic patients with sepsis re-
ceiving high-dose steroids [28, 39, 113, 153, 163]. Thus, high-
dose corticosteroids are not recommended as treatment of
sepsis (EI).
Low-dose corticosteroid treatment (≤300 mg hydrocortisone
per day)
Substitutive doses of hydrocortisone during sepsis remain
controversial. Annane et al. identified a benefit in 28-day
mortality for the treatment group [14]. The CORTICUS trial
did not reveal a difference in 28-day mortality between treat-
ment and placebo and found a higher incidence of
hyperglycaemia, hypernatraemia and secondary infections in
the treatment group [152]. The results of meta-analyses have
been similarly contradictory. Some meta-analyses support the
use of low doses of hydrocortisone [12, 114, 150], while
others do not support the use of low doses of hydrocortisone
[80, 116, 146]. Newer data from three observational studies
with a total of over 25,000 patients from sepsis registries
showed no mortality benefit for low-doses steroids [25, 33,
49]. Thus, we do not recommend the routine use of substitu-
tive doses of hydrocortisone in neutropenic patients with
sepsis (DI). However, low-dose corticoid treatment may be
considered in patients with insufficient restoration of blood
pressure levels despite adequate fluid resuscitation and vaso-
pressor treatment (BII) [124]. The results of three ongoing
large randomized controlled trials will hopefully further clar-
ify the role of low-dose steroids in severe sepsis.
Treatment with coagulation inhibitors
In sepsis, the coagulation cascade is frequently activated at
early time points. As thrombocytopenia and an increased risk
of bleeding are frequently present in patients with cancer and
chemotherapy, attempts to positively influence coagulation in
patients with neutropenia have to be exerted carefully.
Heparin
Retrospective trials in patients with sepsis have shown a
reduction in mortality using unfractionated heparin [170].
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The prospective randomized controlled HETRASE study has
investigated treatment with low-dose heparin (500 IU/h dur-
ing 7 days) in 319 patients with sepsis [77]. No influence on
28-day all-cause mortality was found. This trial was charac-
terized by low mortality, perhaps explained by liberal inclu-
sion criteria. Treatment was discontinued when the partial
thromboplastin time exceeded 60 s. Under these conditions,
the administration of low-dose heparin was safe. Further trials
including more patients and defined subgroups are needed
before recommendations for the use of heparin in neutropenic
sepsis can be made (CI).
Antithrombin
Antithrombin has anti-thrombotic and anti-inflammatory
properties. Based on the negative data from the KyberSept
trial [165], a Cochrane analysis [4], and subgroup analyses of
several trials [72, 87, 167], we do not recommend the routine
use of antithrombin as treatment of neutropenic sepsis in the
absence of disseminated intravascular coagulation (DIC; DI).
However, in patients with DIC and sepsis, the administration
of antithrombin may be considered (BII) [87].
Activated protein C (APC)
In response to the results of the PROWESS-SHOCK trial
[136], APC is no longer in use.
Thrombomodulin
Thrombomodulin decreases thrombus formation, activates
protein C and has anti-inflammatory properties [2, 119, 148,
161]. Results from a phase IIb study suggested efficacy in
patients with sepsis and suspected DIC [161]. However, safety
and efficacy is not known in cytopenic patients, and no
evidence-based recommendation can be made.
Cytokines and haematopoietic growth factors (G-CSF,
GM-CSF)
The central role of cytokines during the hyper- and anti-
inflammatory phases of sepsis prompted clinical studies on
the use of cytokines and cytokine inhibitors as therapeutic
agents. However, studies on the therapeutic efficacy of IL-1
receptor antagonist, TNF-inhibitors, TLR-4 inhibitors and
interferon gamma did not show a clinical benefit (EI) [52,
53, 117, 121, 139].
The known effect of G-CSF and GM-CSF in increasing the
number of circulating granulocytes was the rationale for clin-
ical studies assessing their role as additional therapy to anti-
biotics in febrile patients with chemotherapy-induced neutro-
penia. A meta-analysis of 13 randomized controlled trials
including a total of 1,518 patients showed that G-CSF/GM-
Table 5 Summary of treatment recommendations given by the Infectious





Initial treatment with meropenem or with imipenem/
cilastatin or with piperacillin/tazobactam
AIII
A combination treatment with an aminoglycoside in




Albumin-containing solutions may be used in patients with
sepsis and septic shock
CII
The drug of choice to elevate the vasotonus is
norepinephrine
BII
In case of sepsis-related myocardial depression leading to
low cardiac output despite adequate volume substitution,
vasopressor treatment with dobutamine should be
instituted
AII
Treatment of pulmonary failure
Non-invasive positive pressure ventilation (CPAP or bilevel
positive airway pressure) should be preferred if possible
in patients without hypotension or altered mental status
AII
An early start of non-invasive ventilation, prior to
development of severe hypoxaemia, is favourable
BII
Management of renal dysfunction
Intermittent haemodialysis and continuous renal
replacement therapies are equivalent
BI
No firm recommendations can be given for the use of
increased doses of renal replacement therapy
CI
Low-dose dopamine for protection of renal function is not
recommended
EI
Nutrition and control of metabolic functions
Enteral nutrition is preferred over parenteral nutrition BII
During initial phase of sepsis, energy supply should not
exceed 20–25 kcal/kg ideal bodyweight (IBW)
DIII
During recovery, 25–30 kcal/kg IBW should be provided BIII
We do not recommend general use of arginine, omega-3
fatty acids and combined formulations in patients with
severe sepsis and septic shock
DII
Glutamine substitution cannot be recommended in patients
with severe sepsis and septic shock
EI
Further clinical trials regarding the adequate dosing and
treatment duration are needed before treatment with
selenium can be recommended
DI
Aiming at strictly normal blood glucose level of 4.4–
6.6 mmol/L (80–120 mg/dL) is not recommended
EI
Blood glucose levels should be kept ≤9.9 mmol/L
(≤180 mg/dL) in septic neutropenic patients
BIII
A high variability of blood glucose levels in septic patients




High-dose corticosteroids should not be used in neutropenic
or non-neutropenic septic patients
EI
The routine use of substitutive doses of hydrocortisone in
neutropenic patients with sepsis is not recommended
DI
Low-dose corticoid treatment may be considered in patients
with insufficient restoration of blood pressure levels
despite adequate fluid resuscitation and vasopressor
treatment
BII
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CSF effectively reduces the time to neutrophil recovery and
the length of hospitalization [36]. However, despite a margin-
ally significant benefit for the use of G-CSF/GM-CSF in
reducing infection-related mortality, overall mortality ap-
peared not to be influenced. Even though this meta-analysis
reported only mild side effects associated with G-CSF/GM-
CSF treatment (bone pain, joint pain and flue-like symptoms),
there is an accumulating number of publications on respiratory
deterioration with ARDS during G-CSF/GM-CSF-induced
neutropenia recovery [17, 18, 83, 147]. In non-neutropenic
patients with pneumonia or sepsis, G-CSF/GM-CSF appeared
to be safe but ineffective in reducing mortality rates or com-
plications from infection [141, 169]. On the basis of the
current studies and reports, we do not recommend the routine
additional use of G-CSF or GM-CSF to standard treatment of
sepsis in neutropenia (DI). Although GM-CSF seems to be
able to reverse sepsis-induced immune paralysis, it is currently
not available for treatment in the EU [110, 143].
Immunoglobulins
The treatment of sepsis in neutropenia with i.v. immunoglob-
ulin’s (IVIG) did not show a significant difference in survival
in a randomized controlled trial [65]. A meta-analysis on trials
of IVIG in patients with sepsis identified 20 trials eligible for
evaluation [156]. Compared with placebo or no intervention,
the use of polyclonal IVIG was associated with a survival
benefit (relative risk 0.74). The number needed to treat to save
one life was nine. Interestingly, more severely ill patients,
those receiving treatment for more than 2 days and those
receiving ≥1 g/kg, seemed to benefit most. As most of the
individual trials analyzed had flaws in design, were rather
small or performed during a time when the standard of care
for septic patients was different from today; the authors con-
clude that a large randomized controlled trial should be per-
formed [156]. Three additional meta-analyses investigated the
use of IVIG during sepsis and had similar outcomes [90, 94,
151]. In conclusion, there is moderate degree of evidence to
support the use of IVIG in sepsis (BII).
Granulocyte transfusions
Several case reports and phase I/II studies have shown some
efficacy of granulocyte transfusions in patients with infections
during severe neutropenia including patients with invasive
fungal infections. However, complications have been reported
as well, e.g. fatal CMV infection, allo-immunization and the
transfusion-related acute lung injury syndrome. Recently, a
randomized controlled trial has been published [101]. It failed
to show any beneficial effect, but it was small, and the authors
discussed several problems associated with the design of the
trial. A meta-analysis of the use of granulocyte transfusion in
neutropenic neonates yielded equivocal results [123]. Taken
together, at this time, no recommendation can be given on the
use of granulocyte transfusions outside of clinical trials.
Transfusion management in sepsis
The recommendations for substituting platelets or packed red
blood cell in neutropenic patients can be applied to those
patients developing sepsis as well. However, the cutoff for
substitution is often set to higher values (platelets 20,000/μL
instead of 10,000/μL; BIII). A randomized trial in children
with sepsis showed no difference in outcome between a liberal
(<9.5 g/dL) and a restrictive (<7 g/dL) trigger for erythrocyte
transfusion [82]. Although there are no prospective random-
ized studies available, we recommend a transfusion trigger of
<9 g/dL haemoglobin level to optimize tissue oxygenation
(there was no consensus inside the panel of experts regarding
the strength of recommendation) [166].
Summary of recommendations
Table 5 summarizes treatment recommendations given by the
AGIHO.
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Treatment with coagulation inhibitors
Further trials on the use of low-dose heparin (500 IU/h for
7 days) are needed before recommendations can be made
CI
Routine use of antithrombin is not recommended as
treatment of sepsis in neutropenic patients antithrombin
may be considered during DIC and sepsis
DI
BII
Growth factors and immunoglobulins
The routine additional use of G-CSF or GM-CSF as
standard treatment of sepsis in neutropenia is not
recommended
DI
There is moderate degree of evidence to support the use of
i.v. immunoglobulins in sepsis
BII
Transfusion management
The cut-off for substitution of platelets is often set to a
higher value (platelets 20,000/μL instead of 10,000/μL
during sepsis)
BIII
A transfusion trigger of <9 g/dL haemoglobin during
neutropenic sepsis is recommended
BIII
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